ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Buys AP214 Hormone From Action Pharma For $110 Million

DOW JONES NEWSWIRES Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery, from Action Pharma A/S for $110 million in cash. The health-care company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating into two publicly traded companies: a medical-products business and a pharmaceutical company to be named AbbVie. Abbott will acquire all global rights to develop and market AP214, and will be responsible for funding all future development and commercialization activities. No later milestone payments or royalties will be paid to the Danish biotech company Action Pharma. Abbott currently has two investigational treatments in development for chronic kidney disease: Bardoxolone, which is in Phase 3 development with Reata Pharmaceuticals, and Atrasentan, a compound discovered by Abbott being evaluated in a Phase 2b study. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

Stock News for Abbott Labs (ABT)
DateTimeHeadline
03/24/201717:07:50Statement of Changes in Beneficial Ownership (4)
03/22/201714:47:13Current Report Filing (8-k)
03/22/201709:00:00Abbott Hosts Conference Call for First-Quarter Earnings
03/21/201706:01:32Notice of Effectiveness (effect)
03/20/201716:57:02Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)
03/19/201714:00:00Late-Breaking Data Shows the CardioMEMS HF System is Effective...
03/18/201712:30:00Late-Breaking Data on Abbott's MitraClip® System Show Continued...
03/17/201717:04:39Statement of Changes in Beneficial Ownership (4)
03/17/201707:31:39Proxy Statement (definitive) (def 14a)
03/14/201712:25:53Current Report Filing (8-k)
03/08/201716:15:00Abbott to Present at Barclays Capital 2017 Global Healthcare...
03/08/201709:00:00New Study Results May Lead to a New Standard of Care for In Vitro...
03/07/201717:14:25Registration Statement for Securities to Be Issued in Business...
03/07/201709:00:00Abbott Announces Results of Early Tenders and Consents in Exchange...
03/02/201717:21:19Statement of Changes in Beneficial Ownership (4)
03/02/201717:21:19Statement of Changes in Beneficial Ownership (4)
03/02/201717:19:29Statement of Changes in Beneficial Ownership (4)
03/02/201717:17:53Statement of Changes in Beneficial Ownership (4)
03/02/201717:17:25Statement of Changes in Beneficial Ownership (4)
03/02/201717:16:36Statement of Changes in Beneficial Ownership (4)

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US